Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) has released a performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the year 2025, indicating a mixed financial performance with a slight decline in revenue but a significant increase in net profit [1] Group 2 - The total operating revenue for the year 2025 is reported at 73.416 billion yuan, reflecting a year-on-year decrease of 1.29% [1] - The net profit attributable to shareholders of the listed company is 1.136 billion yuan, which shows a substantial year-on-year increase of 76.8% [1] - The basic earnings per share (EPS) is reported at 2.04 yuan [1]

Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) has released its performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the year 2025, showing a total operating revenue of 73.416 billion yuan, a year-on-year decrease of 1.29% [1] - The net profit attributable to shareholders of the listed company is 1.136 billion yuan, which represents a significant year-on-year increase of 76.8% [1] - The basic earnings per share (EPS) is reported at 2.04 yuan [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the preliminary performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the fiscal year 2025, highlighting a mixed financial performance with a decline in revenue but significant growth in profits [1] Financial Performance Summary - The total operating revenue for China National Pharmaceutical Group Co., Ltd. reached 73.416 billion yuan, representing a year-on-year decrease of 1.29% [1] - Operating profit amounted to 1.513 billion yuan, showing a substantial year-on-year increase of 163.80% [1] - Total profit was reported at 1.509 billion yuan, which is a year-on-year growth of 162.22% [1] - The net profit attributable to shareholders was 1.136 billion yuan, reflecting a year-on-year increase of 76.80% [1] - Basic earnings per share increased by 77.39% year-on-year [1] - The weighted average return on net assets rose by 2.59 percentage points compared to the previous year [1] Factors Influencing Profit Growth - The profit growth was primarily driven by a reduction in asset impairment provisions for goodwill and intangible assets, which decreased by 686 million yuan year-on-year [1] - Additionally, adjustments in store operations led to a decline in fixed costs such as labor and rent [1]

Core Viewpoint - China National Pharmaceutical Group (国药控股) announced the preliminary performance report for China National Pharmaceutical Group Co., Ltd. (国药一致) for the fiscal year 2025, highlighting a mixed performance with a slight decline in revenue but significant growth in profits [1] Financial Performance Summary - The total operating revenue for China National Pharmaceutical Group Co., Ltd. reached 73.416 billion RMB, representing a year-on-year decrease of 1.29% [1] - Operating profit amounted to 1.513 billion RMB, showing a substantial year-on-year increase of 163.80% [1] - Total profit for the period was 1.509 billion RMB, which is a year-on-year growth of 162.22% [1] - Net profit attributable to shareholders was 1.136 billion RMB, reflecting a year-on-year increase of 76.80% [1] - Basic earnings per share increased by 77.39% year-on-year [1] - The weighted average return on equity rose by 2.59 percentage points compared to the previous year [1] Factors Contributing to Profit Growth - The profit growth was primarily driven by a reduction in asset impairment provisions for goodwill and intangible assets, which decreased by 686 million RMB year-on-year [1] - Additionally, adjustments in store operations led to a decrease in fixed costs such as labor and rent [1]

公告 國藥一致2025年度業績快報 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而 引致之任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.09條及證券及期貨條例（香港 法例第571章）第XIVA部刊發。 茲提述國藥控股股份有限公司（「本公司」）於2026年3月17日刊發之海外監管公告 （「該公告」） ， 內容有關本公司附屬公司國藥集團一致藥業股份有限公司（「國藥一 致」，其A股及B股在深圳證券交易所上市（A股股票代碼：000028及B股股票代碼： 200028））之截至2025年12月31日止年度（「報告期」）之年度業績快報。 本公司董事會謹此提醒股東及公眾投資者注意以下於該公告內載列之國藥一致報告期之 主要未經審核財務數據和指標。 * 本公司以其中文名稱及英文名稱「 Sinopharm Group Co. Ltd. 」根據香港公司條例註冊為非香港公司。 1 國藥一致之主要財務數據和指標 單位:萬元 幣種:人民幣 | | 本報告期 | 上年同期 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致之任何損失承擔任何責任。 海外監管公告 國藥集團一致藥業股份有限公司 2025 年度業績快報 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條作出。 茲載列國藥控股股份有限公司旗下一間 A 股及 B 股於深圳證券交易所上市的附屬公司，國藥 集團一致藥業股份有限公司，在深圳證券交易所網站刊登的《國藥集團一致藥業股份有限公 司 2025 年度業績快報》，僅供參閱。 承董事會命 國藥控股股份有限公司 董事長 晉斌 中國，上海 2026 年 3 月 17 日 於本公告日期，執行董事為連萬勇先生及楊秉華先生；非執行董事為晉斌先生、陳啟宇先生、祖敬 先生、邢永剛先生、馬躍先生、陳玉卿先生、文德鏞先生及李瑩女士；獨立非執行董事為李培育先 生、吳德龍先生、俞衛鋒先生、石晟昊先生及陳威如先生。 证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2026-04 国药集团一致药业股份有限公司 2025年度 ...

格隆汇3月12日丨根据联交所最新权益披露资料显示，2026年3月9日，国药控股(01099.HK)获JPMorgan Chase & Co.以每股均价20.4501港元增持好仓74.98万 股，涉资约1533.32万港元。 增持后，JPMorgan Chase & Co.最新持好仓数目为6767.56万股，持好仓比例由4.98%上升至5.04%。 | 股份代號: | 01099 | | --- | --- | | 上市法國名稱: | 國藥控股股份有限公司 - HJ | | 日期 (日 / 月 / 年): | 12/02/2026 - 12/03/2026 | | 部位 200 | 般東/董事/最高行政人員名 作出披露的買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關車件的日 相關法 | | --- | --- | --- | --- | --- | --- | --- | | | 版分别言 | | | | 精彩图 拉* 部 | 有投票權股票(日/月/ 權益 | | | | | | | | 份自分享 | | CS20260312E00268 | JPMorgan C ...

Group 1 - Morgan Stanley increased its stake in China National Pharmaceutical Group (01099) by 749,784 shares at a price of HKD 20.4501 per share, totaling approximately HKD 15.33 million [1] - After the increase, the total number of shares held by Morgan Stanley is approximately 67,675,600, representing a holding percentage of 5.04% [1]

智通财经APP获悉，香港联交所最新资料显示，3月9日，摩根大通增持国药控股(01099)74.9784万股， 每股作价20.4501港元，总金额约为1533.32万港元。增持后最新持股数目约为6767.56万股，最新持股比 例为5.04%。 ...

Group 1 - The core point of the article is that China National Pharmaceutical Group (国药控股) will hold a board meeting on March 20, 2026, to consider and approve the annual performance for the twelve months ending December 31, 2025, and to declare dividends if applicable [1] Group 2 - The meeting is scheduled for a Friday, indicating a strategic timing for financial disclosures [1] - The focus will be on both the company and its subsidiaries, highlighting the importance of consolidated performance [1] - The announcement suggests a forward-looking approach to financial management and shareholder returns [1]